NCT06623656 2026-04-21
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
Weill Medical College of Cornell University
Phase 2 Recruiting
Clinical Trials
209 trialsNCT07246863 2026-04-21
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
CatalYm GmbH
Phase 2 Recruiting
NCT07419295 2026-04-21
TroFuse-031
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06545955 2026-04-20
ABLE-22
Ferring Pharmaceuticals
Phase 3 Recruiting
NCT06551324 2026-04-20
MEVPRO-1
Pfizer
Phase 3 Recruiting
NCT06661122 2026-04-20
HAYATE
Bayer
Recruiting
NCT06857175 2026-04-20
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT06863272 2026-04-20
IDeate-Prostate02
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06925737 2026-04-20
MK-2400-001
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT01810913 2026-04-17
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2/3 Recruiting
NCT06042569 2026-04-17
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
City of Hope Medical Center
Phase 2 Recruiting
NCT06353386 2026-04-17
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06952504 2026-04-17
TroFuse-033
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07322263 2026-04-17
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
University of Iowa
Phase 2 Recruiting
NCT02128906 2026-04-16
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
University of Pittsburgh
Phase 2 Recruiting
NCT04615013 2026-04-16
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06439225 2026-04-16
OPTION-DDR
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT07213674 2026-04-16
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Amgen
Phase 3 Recruiting
NCT03317158 2026-04-15
ADAPT-BLADDER
Hoosier Cancer Research Network
Phase 1/2 Recruiting
NCT05910827 2026-04-15
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Hummingbird Bioscience
Phase 1/2 Recruiting
NCT06524544 2026-04-15
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06615752 2026-04-15
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
Charles Drew University of Medicine and Science
Phase 1/2 Recruiting
NCT06741644 2026-04-15
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1/2 Recruiting
NCT06745908 2026-04-15
ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer
ImmunityBio, Inc.
Phase 3 Recruiting
NCT04577014 2026-04-14
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT04928846 2026-04-14
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie
Phase 3 Recruiting
NCT05142189 2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1 Recruiting
NCT05382559 2026-04-14
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT05671510 2026-04-14
PRESERVE-003
OncoC4, Inc.
Phase 3 Recruiting
NCT06592924 2026-04-14
TRIPLE-SWITCH
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT07225946 2026-04-14
KLK2-PASenger
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT07528274 2026-04-14
Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT04895709 2026-04-13
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT05818683 2026-04-13
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06498648 2026-04-13
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT06928389 2026-04-09
NSCLC
Akeso
Phase 3 Recruiting
NCT04633252 2026-04-08
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT06989112 2026-04-08
DE-01
AstraZeneca
Phase 3 Recruiting
NCT07287150 2026-04-08
InavoPC
Hoffmann-La Roche
Phase 2 Recruiting
NCT07441460 2026-04-08
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Shanghai JMT-Bio Inc.
Phase 3 Recruiting
NCT05184803 2026-04-07
A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer
Asan Medical Center
Phase 2 Recruiting
NCT06632327 2026-04-07
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT06931340 2026-04-07
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT03801876 2026-04-03
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
NRG Oncology
Phase 3 Recruiting
NCT05408845 2026-04-03
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
NRG Oncology
Phase 2 Recruiting
NCT07001618 2026-04-03
IMMUNOLIFE2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Recruiting
NCT07017673 2026-04-02
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT06472245 2026-04-01
ARTEMIA
OSE Immunotherapeutics
Phase 3 Recruiting
NCT06780098 2026-04-01
MK-3475-01I
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT06340568 2026-03-31
Fern-EC-01
BioNTech SE
Phase 3 Recruiting